<DOC>
	<DOCNO>NCT00030654</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs luteinizing hormone-releasing hormone agonist , flutamide , bicalutamide may stop adrenal gland produce androgen . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining hormone therapy chemotherapy may kill tumor cell . It yet know whether chemotherapy give time hormone therapy effective chemotherapy give hormone therapy treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy give time hormone therapy chemotherapy give hormone therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Plus Chemotherapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient high-risk hormone-naive prostate cancer treat androgen blockade concurrent chemotherapy v delay chemotherapy . Secondary - Compare biochemical control patient treat regimen . - Determine toxicity regimens patient . - Compare time clinical failure , measure progression bone scan CT scan prostate-specific antigen ( PSA ) double time â‰¤ 32 week , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord prior therapy ( surgery v radiotherapy and/or brachytherapy v ) , original combine Gleason score ( 6 vs 7 vs 8-10 ) , prior vaccine therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive androgen blockade ( AB ) comprise luteinizing-hormone releasing-hormone agonist continuously oral flutamide oral bicalutamide daily least 1 month . Within 4 week initiation AB , patient begin chemotherapy . Patients receive 1 , 1 , follow chemotherapy regimen : - Regimen A : Patients receive oral estramustine 3 time daily day 1-5 docetaxel IV day 3 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Regimen B : Patients receive oral estramustine 3 time daily day 1-5 paclitaxel IV day 3 , 10 , 17 , 24 , 31 , 38 . Treatment repeat every 56 day 4 course absence disease progression unacceptable toxicity . - Regimen C : Patients receive oral ketoconazole 3 time daily day 1-7 , 15-21 , 29-35 ; doxorubicin IV day 1 , 15 , 29 ; vinblastine IV day 8 , 22 , 36 ; oral estramustine 3 time daily day 8-14 , 22-28 , 36-42 . Treatment repeat every 56 day 4 course absence disease progression unacceptable toxicity . - Regimen D : Patients receive oral estramustine 3 time daily day 1-4 docetaxel IV 1 hour day 3 , 10 , 17 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Regimen E : Patients receive docetaxel IV day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Regimen F : Patients receive docetaxel IV day 1 , 8 , 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . - Regimen G : With approval protocol chair , patient may receive regimen demonstrate publish phase II study least 50 % response rate measure PSA decrease baseline 2 measurement 28 day apart decrease measurable soft tissue disease 50 % 2 dimension . - Arm II : Patients receive AB arm I . Patients continue AB clinical failure , time patient receive chemotherapy arm I . Patients response may continue receive chemotherapy beyond 4 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 1,050 patient accrue study within 4-6 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Failed local treatment ( surgery and/or radiotherapy and/or brachytherapy ) define rise prostatespecific antigen level least 2.0 ng/mL ( confirmed 2 measurement least 2 week apart ) double time 32 week less No clinical radiographic evidence disease Original Gleason score least 7 OR Gleason score 6 capsular penetration positive seminal vesicle lymph node No metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL No history bleed disorder would contraindicate warfarin , include clot factor defect Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 1.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Blood Urea Nitrogen ( BUN ) great 1.2 time normal Cardiovascular : No symptomatic heart disease No history myocardial infarction No history thromboembolic event ( e.g. , deep vein thrombosis , symptomatic cerebrovascular event , pulmonary embolism ) Other : No major medical psychiatric illness would preclude study entry No prior concurrent invasive malignancy within past 5 year except superficial skin cancer No history esophageal varix Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior vaccine therapy Chemotherapy : At least 5 year since prior chemotherapy Endocrine therapy : Prior adjuvant neoadjuvant hormonal therapy le 8 month duration allow At least 1 year since prior androgen therapy Radiotherapy : See Disease Characteristics At least 5 year since prior radiotherapy site prostate Surgery : See Disease Characteristics Other : Concurrent warfarin allow Concurrent bisphosphonate therapy initiate prior randomization allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>